STTK vs PAXS Comparison

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

PIMCO Access Income Fund is a non-diversified, limited-term, closed-end management investment company. The fund seeks current income as an objective and capital appreciation as a secondary objective. The company achieves the investment objectives by utilizing a dynamic asset allocation among multiple sectors in the public and private credit markets, including corporate debt.